Stage II Ovarian Cancer: Dana's Survivor Story

Patient Info: Dana McKay | Stage II

After surgery and 6 rounds of carboplatin and paclitaxel, she described herself as cancer-free in February 2019.

MD AndersonRead more →

Stage I Ovarian Cancer: Jane's Survivor Story

Patient Info: Jane McGrath, female, 40s | Stage I

Jane was in remission after surgery and 6 rounds of chemotherapy and later became an ovarian-cancer volunteer and advocate.

Memorial Sloan KetteringRead more →

Stage IV Breast Cancer: Nathalie's Patient Story

Patient Info: Nathalie | Stage IV

Nathalie had been living with stage 4 breast cancer for more than three years and remained focused on time with her children.

Our Cancer StoriesRead more →

Aggressive lung cancer with bone metastases and concurrent localized breast cancer

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: Bone: skull, spine, clavicle

The patient was still receiving carboplatin and Taxol for aggressive lung cancer with bone metastases, while her caregiver reported rapid clinical improvement, pain relief, disappearance of a visible forehead metastasis, and 1 cm reduction in a concurrent localized breast tumor.

Stage II BRCA1 Invasive Ductal Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie Hargis, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

Stephanie had Stage II triple-negative breast cancer with BRCA1 mutation, then a local recurrence in April 2023 without distant spread; after surgery, chemotherapy, Keytruda, radiation, and Lynparza, she remained in ongoing post-recurrence treatment.

BreastCancer.org (ES)Read more →

Triple-Negative Invasive Ductal Carcinoma: Katherine's Patient Story

Patient Info: Katherine Humphrey, Female, Under 40

Biomarkers: triple-negative

Recovering after bilateral mastectomy and additional chemotherapy, with capecitabine planned for fall 2026.

Dana-FarberRead more →

HER2-positive breast cancer complicated by severe anemia during chemotherapy

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive; germline BRCA1 likely pathogenic mutation

At 4.5-year follow-up, she remained free of breast-cancer recurrence and had no recurrence of the severe treatment-related anemia.

PubMed CentralRead more →

Stage II Ovarian Cancer: Elizabeth's Survivor Story

Patient Info: Elizabeth Jardinella, Female, Under 40 | Stage II

Cancer-free for about 2 years, with surveillance scans continuing to show no evidence of disease while she takes maintenance letrozole.

MD AndersonRead more →

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed CentralRead more →

Early-stage ovarian squamous cell carcinoma arising in a mature cystic teratoma

Patient Info: Anonymized, female, 50s | Stage I

Biomarkers: ovarian tumor HPV DNA-negative; p16-negative

She achieved complete remission and had no evidence of recurrence 24 months after surgery, at follow-up in June 2026.

PubMed CentralRead more →

A man with lung cancer develops kidney and lung side effects during durvalumab treatment

Patient Info: Anonymized, Male, 60s

Alive at 200 weeks with sustained improvement in proteinuria and kidney injury after durvalumab was discontinued.

PubMed CentralRead more →

More than 5 years living with metastatic lung adenocarcinoma after stepwise molecular testing

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 amplification, EGFR L858R mutation, PD-L1 <1%

Metastatic Site: brain, lung

As of April 2026, she remained on gefitinib with no active tumor lesions after complete regression of lung metastases, more than 5 years (66 months) after her original diagnosis.

PubMed CentralRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

Rare Breast Neuroendocrine Cancer That Recurred in the Liver

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Chromogranin-positive; synaptophysin-positive; GATA-3-positive; ER-positive; PR negative on repeat biopsy and 40% positive on the mastectomy specimen; HER2-negative; Ki-67 85–95%

Metastatic Site: Liver; abdominal lymph nodes

After temporary responses to surgery and repeated chemotherapy, the cancer returned repeatedly in the liver and had spread to abdominal lymph nodes by May 2025. A new chemotherapy regimen was planned.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Whole-liver radiation for Stage IV small cell lung cancer with diffuse liver metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

After renewed liver progression and declining performance status, chemotherapy was stopped and supportive care began. He died in a palliative care unit on July 27, 2019.

PubMed CentralRead more →

Lung adenocarcinoma that spread to the thyroid 9 years later

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: thyroid

After the thyroid metastasis was removed, she started systemic chemotherapy and remained under oncology management.

PubMed CentralRead more →

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →

Stage IV lung cancer presenting with a paraneoplastic neurologic syndrome and mixed tumor features

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 0%

Metastatic Site: bone (T10 and L5 vertebrae)

He died after rapid deterioration with severe encephalopathy, weakness and respiratory distress; advanced metastatic lung cancer with progressive paraneoplastic neurologic involvement was considered the most likely cause.

PubMed CentralRead more →

Stable lung cancer after recovery from a severe immunotherapy complication

Patient Info: Anonymized, Male, 60s

At 8-month follow-up, the primary lung tumor remained radiologically stable on maintenance chemotherapy without evidence of progression.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →